ERBB2 and breast carcinoma: Although a trend for better overall survival was noted in HER2+ breast carcinoma patients that were traditionally considered as an “unfavorable” breast carcinoma subtype [68% alive HER2+ patients at the end of the study period vs, 56% alive patients in ER+/PR+/HER2− (“favorable” subtype) or 58% alive patients in triple negative “unfavorable” subtype], the “favorable” breast carcinoma subtype was not significantly predictive of better overall survival (Figure 1, Kaplan Meier curve, p = 0.285).